<p>Eighteen EDRN developed biomarker tests are available in Clinical Laboratory Improvement Amendments (CLIA) approved laboratories. <a href="fda-approved-tests-and-devices">Eight diagnostic tests or devices supported by the EDRN</a> have also been approved by the U.S. Food and Drug Administration for clinical use.</p>
<p>The CLIA-approved tests are shown in the chart below.</p>
<table class="listing biomarkerTable" summary="Biomarker assays, purposes, and EDRN principal investgators responsible for them" style="border-style: solid; float: left;">
<thead>
<tr>
<th>Biomarker Assay</th>
<th>Purpose</th>
<th>EDRN Principal Investigator<br />CLIA Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiCheck (Glypican-1 protein and related signaling molecules)</td>
<td>Differentiate aggressive prostate cancer from non-aggressive cancer and no cancer</td>
<td>Daniel Chan, Ph.D.<br />Minomic, Inc.</td>
</tr>
<tr>
<td>Videssa (a multi-protein biomarker blood test)</td>
<td>Distinguish benign from malignant breast lesions</td>
<td>Joshua LaBaer, M.D., and Karen Anderson, M.D.<br />Provista</td>
</tr>
<tr>
<td>DetermaVu</td>
<td>Liquid biopsy test intended to facilitate clinical decision making in lung cancer</td>
<td>Louise Showe, Ph.D.<br />OncoCyte</td>
</tr>
<tr>
<td>Precepta</td>
<td>(23-gene expression panel) Detection of lung cancer</td>
<td>Avrum Spira, M.D.<br />Veracyte Inc.</td>
</tr>
<tr>
<td>Esoguard (methylated vimentin and cyclin A1)</td>
<td>Detection of Barrett’s esophagus</td>
<td>Sandford Markowitz, M.D.<br />PAVmed</td>
</tr>
<tr>
<td>Decipher Prostate Cancer Classifier Test (SChLAP1 and other lncRNAs)</td>
<td>Determination of prostate cancer aggressiveness</td>
<td>Arul Chinnaiyan, M.D., Ph.D.<br />GenomeDx</td>
</tr>
<tr>
<td>Protein panel (TIMP1, LRG1 and CA19-9)</td>
<td>Detection of pancreatic cancer</td>
<td>Samir Hanash M.D., Ph.D.<br />Cosmos Wisdom</td>
</tr>
<tr>
<td>Mucin panel (MUC4, MUC5AC, MUC16 and MUC 17)</td>
<td>Detection of pancreatic cancer</td>
<td>Surinder Batra, Ph.D.<br />Sanguine Diagnostic and Therapeutics</td>
</tr>
<tr>
<td>MiPS (Mi Prostate Score Urine test), Multiplex analysis of TMPRSS2:ERG gene fusion, PCA3 and serum PSA</td>
<td>Detection of prostate cancer</td>
<td>Arul Chinnaiyan, M.D., Ph.D.<br />Gen-Probe</td>
</tr>
<tr>
<td>IHC and FISH for TMPRSS2:ERG fusion</td>
<td>Detection of prostate cancer</td>
<td>Arul Chinnaiyan, M.D., Ph.D.<br />Roche</td>
</tr>
<tr>
<td>GSTP1 methylation</td>
<td>Decision making regarding repeat biopsies in prostate cancer</td>
<td>David Sidransky, M.D.<br />OncoMethylome</td>
</tr>
<tr>
<td>Mitochondrial deletion</td>
<td>Detection of prostate cancer</td>
<td>National Institute of Standards and Technology (NIST)<br />Mitomics</td>
</tr>
<tr>
<td>Proteomic panel</td>
<td>Detection of lung cancer</td>
<td>William Rom, M.D., M.P.H.<br />Celera</td>
</tr>
<tr>
<td>Aptamer-based markers</td>
<td>Detection of lung cancer</td>
<td>William Rom, M.D., M.P.H.<br />Somalogic</td>
</tr>
<tr>
<td>80-gene panel†<br />†This panel has been refined; Percepta®, a 23-gene classifier, is now available through Veracyte)</td>
<td>Detection of lung cancer</td>
<td>Avrum Spira, M.D., M.Sc.<br />Allegro/Veracyte</td>
</tr>
<tr>
<td>Vimentin methylation in stool</td>
<td>Detection of colon cancer</td>
<td>Sanford Markowitz, M.D., Ph.D.<br />LabCorp</td>
</tr>
<tr>
<td>Galectin-3 ligand</td>
<td>Detection of advanced adenomas and colon cancer</td>
<td>Robert Bresalier, M.D.<br />BG Medicine</td>
</tr>
<tr>
<td>GP73</td>
<td>Risk of hepatocellular carcinoma</td>
<td>Timothy Block, Ph.D.<br />Beckman Coulter</td>
</tr>
<tr>
<td>8-gene Panel for Barrett’s Esophagus (BE)</td>
<td>Progression prediction of BE</td>
<td>Stephen Meltzer, M.D.<br />Diagnovus</td>
</tr>
</tbody>
</table>